ArticleExperimental biology and medicine (Maywood, N.J.)2017
Featured Article: Serum [Met
Article in Experimental biology and medicine (Maywood, N.J.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 44 citations in OpenAlex.
- Low-dose naltrexone as an adjunctive treatment for major depressive disorder: findings from a randomized, double-blind, placebo-controlled hybrid parallel-arm study.Frontiers in pharmacology · 2026Trial
- Effects of low-dose naltrexone on quality of life in high-grade glioma patients: a placebo-controlled, double-blind randomized trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Trial
- Opioid Signaling in Multiple Sclerosis: Emerging Targets for Repair.International journal of molecular sciences · 2026Review
- Naltrexone dose-selectively modulates goal-directed behavior and the hypothalamic proteome in rats.Pharmacological reports : PR · 2025Article
- Lifetime exposure to smoking and substance abuse may be associated with late-onset multiple sclerosis: a population-based case-control study.BMC neurology · 2024Article
- Enkephalins and Pain Modulation: Mechanisms of Action and Therapeutic Perspectives.Biomolecules · 2024Review
- Plasma Pro-Enkephalin A and Incident Cognitive Impairment: The Reasons for Geographic and Racial Differences in Stroke Cohort.Journal of the American Heart Association · 2023Article
- Opiate Antagonists for Chronic Pain: A Review on the Benefits of Low-Dose Naltrexone in Arthritis versus Non-Arthritic Diseases.Biomedicines · 2023Review
- Low-dose naltrexone reduced anxiety in persons with multiple sclerosis during the COVID-19 pandemic.International immunopharmacology · 2022Article
- Translocator Protein Ligand PIGA1138 Reduces Disease Symptoms and Severity in Experimental Autoimmune Encephalomyelitis Model of Primary Progressive Multiple Sclerosis.Molecular neurobiology · 2022Article
- Prurigo excoriée treated with low dose naltrexone.BMJ case reports · 2021Article
- Multiple Sclerosis and the Endogenous Opioid System.Frontiers in neuroscience · 2021Review
- Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment.Frontiers in immunology · 2021Article
- Protective effects of pharmacological therapies in animal models of multiple sclerosis: a review of studies 2014-2019.Neural regeneration research · 2020Review
- Intermittent blockade of OGFr and treatment of autoimmune disorders.Experimental biology and medicine (Maywood, N.J.) · 2018Review
- Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization.Medical sciences (Basel, Switzerland) · 2018Review
- Article
- Featured Article: Modulation of the OGF-OGFr pathway alters cytokine profiles in experimental autoimmune encephalomyelitis and multiple sclerosis.Experimental biology and medicine (Maywood, N.J.) · 2018Article
- Exploring the relationships of physical, mental, and emotional symptoms and serum biomarkers of angiogenesis in multiple sclerosis.Multiple sclerosis journal - experimental, translational and clinicalArticle
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Low-dose naltrexone is a widely used off-label therapeutic prescribed for a variety of immune-related disorders. The mechanism underlying low-dose naltrexone's efficacy for fatigue, Crohn's disease, fibromyalgia, and multiple sclerosis is, in part, intermittent blockade of opioid receptors followed by upregulation of endogenous opioids. Short, intermittent blockade by naltrexone specifically blocks the opioid growth factor receptor resulting in biofeedback events that increase production of the endogenous opioid growth factor (OGF) (chemically termed [Met
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.